Incyte Corp

NASDAQ: INCY
$52.94
+$0.89 (+1.7%)
Closing price May 1, 2024
Incyte Corp is a biopharmaceutical company focused on developing and commercializing treatments for cancer and autoimmune diseases. It is known for its flagship product, JAKAFI, used in treating various blood-related disorders, and has a diverse portfolio including therapies for leukemia, lymphoma, and skin diseases. Incyte is actively involved in research, with several products in clinical trials aiming to address unmet medical needs in oncology and inflammation. The company collaborates with other pharmaceutical entities to expand its reach and improve patient care globally. Headquartered in Wilmington, Delaware, Incyte continues to innovate in the healthcare space.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
The top analyst upgrades, downgrades and other research calls from Wednesday include AutoZone, Chipotle Mexican Grill, Diamondback Energy, Hasbro, Papa John’s and Western Digital.
These are five stocks that the top hedge funds are buying, none of which is an overbought and crowded tech stock. They all make good sense for growth accounts with some risk tolerance.
The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford, Kinder Morgan, Pandora Media, Procter &...
Tuesday was a positive day for the broad U.S. markets with each of the major exchanges recovering, if only slightly, from Monday. Crude oil was pushed much higher in the session, retreating over $70....
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Thursday was another positive day for the broad U.S. markets. Although markets were solid throughout the day, there was a small dip at the end from some selling pressure. At the same time, crude oil...
Acadia Pharmaceuticals, Veo, Sibanye Gold, and Incyte Pharmaceuticals all posted new 52-week lows Monday.
The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint and Regeneron Pharmaceuticals.
24/7 Wall St. perused all 86 picks from the Credit Suisse top picks list and picked out the few names that are still targeting upside of more than 50%.
Incyte, NewLink Genetics, McDermott International, and Williams Companies all posted new 52-week low Friday.
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
Thursday was a strong day for the U.S. markets, with all three of the major exchanges hitting all-time highs yet again. Earnings season is just around the corner, and starting Friday we will finally...
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.